Results of the 2023 Annual General Meeting of shareholders and resumption of the liquidity contract

All proposed resolutions submitted to the AGM were approved, as outlined below.

Following the approval of agenda item 7, and effective as of July 03, 2023, the company reinstates the liquidity contract with Invest Securities that was temporarily suspended as of March 28, 2023. As a reminder, TME Pharma have signed the liquidity agreement with INVEST SECURITIES on September 12, 2016. This agreement complies with the AMAFI Chart and with the decision of the French Financial Market Authority (Autorité des marchés financiers or AMF) N°2021-01 of June 22, 2021, establishing an accepted market practice in relation to liquidity contracts on shares and any other provisions referred to therein. The number of shares and cash balance allocated to the Liquidity Contract on March 28, 2023, the date of suspension, were 14,630 shares and €15,971.59.

In compliance with TME Pharma 2023 AGM dated June 29, 2023, the buy-back program authorized the company to acquire its own shares with a minimum price of €0.01 and a maximum price of €50.00.

About the GLORIA Study

GLORIA (NCT04121455) is TME Pharma’s dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 three additional arms combining NOX-A12 with: A. radiotherapy in patients with complete tumor resection; B. radiotherapy and bevacizumab; and C. radiotherapy and pembrolizumab.

About the OPTIMUS Study

OPTIMUS (NCT04901741) is TME Pharma’s planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Disclaimer

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements.” Forward-looking statements are based on TME Pharma’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma’s ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and TME Pharma undertakes no duty to update such information except as required under applicable law. 

Download the full press release in PDF : FR – EN